RPT

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Retrieved on: 
Monday, February 26, 2024

Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).
  • With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb.
  • “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Kimco Realty® Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024

Kimco Realty® (NYSE: KIM), North America’s largest publicly listed owner and operator of open-air, grocery-anchored shopping centers and a growing portfolio of mixed-use assets, today reported results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Kimco Realty® (NYSE: KIM), North America’s largest publicly listed owner and operator of open-air, grocery-anchored shopping centers and a growing portfolio of mixed-use assets, today reported results for the fourth quarter and full year ended December 31, 2023.
  • “We ended the year with strong results, including leasing an impressive 2.7 million square feet, and achieving positive net absorption and double-digit leasing spreads for the quarter,” said Kimco CEO Conor Flynn.
  • FFO was $239.4 million, or $0.39 per diluted share, compared to $234.9 million, or $0.38 per diluted share, for the fourth quarter of 2022.
  • FFO for the fourth quarter of 2023 included $1.0 million of merger-related charges.

Alaska Energy Metals Provides Corporate Update

Retrieved on: 
Tuesday, January 30, 2024

VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to provide a corporate update that highlights the accomplishments made since inception in April 2023 and looks ahead to 2024 plans.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to provide a corporate update that highlights the accomplishments made since inception in April 2023 and looks ahead to 2024 plans.
  • Alaska Energy Metals Corporation President & CEO Gregory Beischer commented: “I am very proud of what we have accomplished in just 10 months.
  • Last year, we also purchased a company that owns a Quebec nickel project, which came with $2.8 million in cash.
  • After deportment studies are complete, the samples will be subjected to bench-scale flotation testing to determine recovery rates for the metals.

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

Retrieved on: 
Tuesday, January 30, 2024

GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.

Key Points: 
  • GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.
  • Under the terms of the agreement, ITM will supply its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a.
  • 177Lu for the clinical development of Alpha-9 radiopharmaceutical candidates comprising n.c.a.
  • ITM holds a U.S. Drug Master File (DMF) with the Food and Drug Administration (FDA) for n.c.a.

Rapsodo Partners with Titleist to Further Enhance the Premium Member Experience for the Rapsodo MLM2PRO

Retrieved on: 
Tuesday, January 23, 2024

Titleist and Rapsodo have partnered to apply the RPT pattern to the #1 ball in golf.

Key Points: 
  • Titleist and Rapsodo have partnered to apply the RPT pattern to the #1 ball in golf.
  • Pro V1 and Pro V1x with RPT will enable MLM2PRO™ to measure spin rate and spin axis.
  • In order to gain access to the spin measurements, users must have a Rapsodo MLM2PRO™ Premium Membership account ($199 annually, included in initial purchase).
  • “The Pro V1 performance golfers trust on the course is now accurately measured wherever you choose to play with your Rapsodo MLM2PRO.

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Retrieved on: 
Friday, January 5, 2024

SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate.

Key Points: 
  • The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment.
  • This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 (64Cu) for imaging and alpha-particle targeted RPT using lead-212 (212Pb).
  • “This innovative approach developed by Mayo Clinic allows for more precise and personalized treatment plans,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site

Retrieved on: 
Thursday, January 4, 2024

Lutetium-177

Key Points: 
  • Lutetium-177
    Garching / Munich, January 4, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the receipt of the Radioactive Material Handling License (RAM License) for the company’s NOVA facility , the world’s largest Lutetium-177 production site.
  • Having obtained the RAM License together with other regulatory approvals required, ITM has achieved operational readiness.
  • The fit-out of NOVA has been completed, with all major production, safety and quality control systems installed.
  • Based on its size and production scale, NOVA could potentially serve up to several hundred thousand patients worldwide per year.

Kimco Realty® Closes Acquisition of RPT Realty

Retrieved on: 
Tuesday, January 2, 2024

Kimco Realty® (“Kimco” or the “Company”) (NYSE: KIM), North America’s largest publicly traded owner and operator of open-air, grocery-anchored shopping centers and a growing portfolio of mixed-use assets, today announced the completion of its previously announced acquisition of RPT Realty (“RPT”).

Key Points: 
  • Kimco Realty® (“Kimco” or the “Company”) (NYSE: KIM), North America’s largest publicly traded owner and operator of open-air, grocery-anchored shopping centers and a growing portfolio of mixed-use assets, today announced the completion of its previously announced acquisition of RPT Realty (“RPT”).
  • The acquisition of RPT adds 56 open-air shopping centers, 43 of which are wholly owned, comprising 13.3 million square feet of gross leasable area, to Kimco’s existing portfolio of 527 properties.
  • J.P. Morgan acted as exclusive financial advisor and Wachtell, Lipton, Rosen & Katz acted as legal advisor to Kimco in connection with the acquisition.
  • Lazard acted as exclusive financial advisor and Goodwin Procter LLP acted as legal advisor to RPT.

RPT Realty Shareholders Approve Mergers

Retrieved on: 
Tuesday, December 12, 2023

NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) (“RPT” or the “Company”) announced today that, at a special meeting of the shareholders of RPT (the “Special Meeting”), the RPT shareholders approved the proposal necessary for the closing of the previously announced mergers pursuant to the Agreement and Plan of Merger, dated as of August 28, 2023 (the “Merger Agreement”), by and among Kimco Realty Corporation (“Kimco”), Kimco Realty OP, LLC, a Delaware limited liability company and wholly owned subsidiary of Kimco (“Kimco OP”), Tarpon Acquisition Sub, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of Kimco (“Merger Sub”), Tarpon OP Acquisition Sub, LLC, a Delaware limited liability company and direct wholly owned subsidiary of Kimco OP (“OP Merger Sub”), RPT and RPT Realty, L.P., a Delaware limited partnership (“RPT OP”), whereby (i) OP Merger Sub will merge with and into RPT OP, with RPT OP surviving the partnership merger (the “Partnership Merger”), (ii) RPT will merge with and into Merger Sub (the “Company Merger” and, together with the Partnership Merger, the “Mergers”), with Merger Sub surviving the Company Merger as a wholly owned subsidiary of Kimco and (iii) immediately after the Company Merger, Kimco will contribute all outstanding membership interests of Merger Sub to Kimco OP.

Key Points: 
  • NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) (“RPT” or the “Company”) announced today that, at a special meeting of the shareholders of RPT (the “Special Meeting”), the RPT shareholders approved the proposal necessary for the closing of the previously announced mergers pursuant to the Agreement and Plan of Merger, dated as of August 28, 2023 (the “Merger Agreement”), by and among Kimco Realty Corporation (“Kimco”), Kimco Realty OP, LLC, a Delaware limited liability company and wholly owned subsidiary of Kimco (“Kimco OP”), Tarpon Acquisition Sub, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of Kimco (“Merger Sub”), Tarpon OP Acquisition Sub, LLC, a Delaware limited liability company and direct wholly owned subsidiary of Kimco OP (“OP Merger Sub”), RPT and RPT Realty, L.P., a Delaware limited partnership (“RPT OP”), whereby (i) OP Merger Sub will merge with and into RPT OP, with RPT OP surviving the partnership merger (the “Partnership Merger”), (ii) RPT will merge with and into Merger Sub (the “Company Merger” and, together with the Partnership Merger, the “Mergers”), with Merger Sub surviving the Company Merger as a wholly owned subsidiary of Kimco and (iii) immediately after the Company Merger, Kimco will contribute all outstanding membership interests of Merger Sub to Kimco OP.
  • The final voting results will be reported on a Form 8-K filed with the Securities and Exchange Commission by RPT with respect to the Special Meeting.
  • The Mergers are expected to close on January 2, 2024, subject to the satisfaction or waiver of customary closing conditions.
  • Upon completion of the Mergers, the common stock of the combined company will trade under the ticker symbol “KIM” on the NYSE, and RPT’s common shares will be delisted from the NYSE.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – PFIN, RPT, PCTI, CSTR

Retrieved on: 
Tuesday, December 5, 2023

Under the terms of the agreement, PFIN shareholders are expected to receive $13.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, PFIN shareholders are expected to receive $13.00 in cash per share they own.
  • RPT Realty (NYSE: RPT ), relating to its proposed merger with Kimco Realty.
  • Under the terms of the agreement, RPT shareholders are expected to receive 0.6049 shares of Kimco per share they own.
  • Under the terms of the agreement, CSTR shareholders will receive 1.155 shares of Old National per share they own.